Skip to content
Caris Life Sciences®

Caris Life Sciences®

Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI.

Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease.

This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.

Logo Caris Life Sciences

    Tumour Biopsy Molecular Profiling (MI Tumor Seek)

    Caris Life Sciences®

    MI Tumor Seek™ is a Next-Generation Sequencing (NGS)-based tumour profiling service that includes Whole Exome Sequencing (WES) analysis of DNA for mutations, copy number alterations*, insertions/deletions, genomic signatures (MSI, TMB*,…

    Book Test

    Comprehensive Tumour Profiling (MI Profile)

    Caris Life Sciences®

    Caris MI Profile™ is a comprehensive tumour profiling platform designed to guide precision oncology. Through advanced whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis, Caris MI Profile™…

    Book Test

    Caris Assure®: Blood based tumour profiling

    Caris Life Sciences®

    Introduction Caris Assure® is blood based comprehensive molecular profiling designed for patients with previously diagnosed solid tumours when tissue biopsy is not feasible. It combines whole-exome sequencing (WES) of cell-free…

    Book Test
Logo of the Scottish Prostate Cancer Initiative featuring a stylised white ribbon on a blue background, with the initiative's name in bold blue and grey text to the right.

The Scottish Prostate Cancer Initiative

The Scottish Prostate Cancer Initiative is a new project which aims to improve early detection and diagnosis of prostate cancer.